Avita Medical (RCEL) Stock Price, News, Quotes-Moomoo

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Avita Medical's Total Revenue Climbs 44% in Q3; Net Loss Widens
MT NewswiresNov 10 17:22 ET
Avita Medical Target Price Raised 28% to A$4.60/Share by Bell Potter>AVH.AU
Dow JonesNov 10 17:18 ET
AVITA Medical, Inc. (RCEL) Q3 2024 Earnings Call Transcript
Earnings Call TranscriptsNov 9 06:39 ET
Lake Street Maintains Avita Medical(RCEL.US) With Buy Rating, Cuts Target Price to $20
Moomoo NewsNov 8 10:31 ET · Ratings
AVITA Medical to Host Investor Webinar Briefing
GlobeNewswireNov 8 09:00 ET
Express News | Piper Sandler Reiterates Neutral on AVITA Medical, Raises Price Target to $12
BenzingaNov 8 08:55 ET

Comments

Jaguar8

May 30 08:16

NEWS

$Avita Medical (RCEL.US)$
AVITA Medical Announces FDA Approval of RECELL GO
AVITA Medical announced FDA approval for its advanced autologous cell harvesting device, RECELL GO. This next-gen device improves treatment for thermal burn wounds and full-thickness skin defects by harnessing a patient's own skin. Key advantages include faster healing, reduced pain, improved aesthetics, and fewer procedures. Enhanced features streamline the preparation of Spray-On Skin Cells and improve workflow effi...

Moomoo AI

Jan 21 15:54

Cantor Fitzgerald sees AVITA's superior growth and high gross margins as reasons for a premium. The firm also sees potential in Pacific Biosciences and AxoGen, and expects positive share price appreciation for Exagen and NeuroPace. A significant catalyst for Nyxoah's stock is anticipated with upcoming DREAM study data.

Cantor Picks RCEL as Best 2024 Medtech Idea; Bullish on PACB, AXGN, CERS

Moomoo AI

Jan 10 08:09

AVITA Medical's CEO, Jim Corbett, is satisfied with the company's growth and is committed to sustaining it in 2024. The ongoing TONE study could influence future business strategies by providing insights into vitiligo's impact on patients' mental health and healthcare costs.

Press Release: AVITA Medical Announces Preliminary 2023 Financial Highlights, Provides 2024 Financial Guidance and Business Update

1

Moomoo AI

Oct 20, 2023 13:31

Despite strong performance, AVITA Medical's P/S ratio remains low, as investors fear possible revenue growth deceleration. The company's growth projection lags behind the industry's, potentially contributing to its low P/S ratio. Without significant revenue improvements, the stock price may stall.

Why Investors Shouldn't Be Surprised By AVITA Medical, Inc.'s (NASDAQ:RCEL) 32% Share Price Plunge

Moomoo Breakfast US

Sep 13, 2022 07:42

Columns Today's Pre-Market Stock Movers: ORCL, RENT, U, AKRO and More

Gapping up
In reaction to earnings/guidance:
• $Planet Labs PBC (PL.US)$ +11.3%, $Core & Main (CNM.US)$ +6.1%, $Regal Rexnord (RRX.US)$ +2% (reaffirms outlook), $Oracle (ORCL.US)$ +1.6%
Other news:
• $Akero Therapeutics (AKRO.US)$ +93.2% (reports Phase 2b HARMONY Study)
• $Akouos (AKUS.US)$ +10.3% (FDA clears IND application to initiate a Phase 1/2 first in human pediatric clinical trial of AK-OTOF)
• $Catalyst Pharmaceuticals (CPRX.US)$ +7.7...

10

RCEL Avita Medical

Trade Overview

Capital Trend

News

Comments

Analysis

Analyst Rating

Price Target